Evidence map›Paper›PMID 31678930›Full record

ArticleMolecular & cellular proteomics : MCP2020

Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion.

Antoine Méant, Beichen Gao, Geneviève Lavoie, Sami Nourreddine, Flora Jung, Léo Aubert, Joseph Tcherkezian, Anne-Claude Gingras, Philippe P Roux

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Article
  8. Mass Spectrometry-Based Discovery ofMass spectrometry (Tokyo, Japan) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Antoine MéantInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.
Beichen GaoInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.
Geneviève LavoieInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.
Sami NourreddineInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.
Flora JungInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.
Léo AubertInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.
Joseph TcherkezianInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada.
Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
Philippe P RouxInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, Québec, Canada; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada. Electronic address: philippe.roux@umontreal.ca.
Institute for Research in Immunology and Cancer · CAUniversity of Toronto · CA

Funding

CIHR
6 · The paper itself

Abstract

The RAS/mitogen-activated protein kinase (MAPK) signaling pathway regulates various biological functions, including cell survival, proliferation and migration. This pathway is frequently deregulated in cancer, including melanoma, which is the most aggressive form of skin cancer. RSK (p90 ribosomal S6 kinase) is a MAPK-activated protein kinase required for melanoma growth and proliferation, but relatively little is known about its function and the nature of its cellular partners. In this study, we used a proximity-based labeling approach to identify RSK proximity partners in cells. We identified many potential RSK-interacting proteins, including p120ctn (p120-catenin), which is an essential component of adherens junction (AJ). We found that RSK phosphorylates p120ctn on Ser320, which appears to be constitutively phosphorylated in melanoma cells. We also found that RSK inhibition increases melanoma cell-cell adhesion, suggesting that constitutive RAS/MAPK signaling negatively regulates AJ integrity. Together, our results indicate that RSK plays an important role in the regulation of melanoma cell-cell adhesion.

Indexed as

CateninsCell AdhesionCell Line, TumorDelta CateninHEK293 CellsHumansMAP Kinase Signaling SystemMelanomaMitogen-Activated Protein KinasesPhosphorylationProteomicsRibosomal Protein S6 Kinases, 90-kDaRNA InterferenceSignal TransductionCateninsCTNND1 protein, humanDelta CateninMitogen-Activated Protein Kinasesribosomal protein S6 kinase, 90kDa, polypeptide 3Ribosomal Protein S6 Kinases, 90-kDaRPS6KA1 protein, humanadherens junctionBRAFCell-cell interactionsMAPKmelanomap120ctnphosphorylationprotein kinasesprotein-protein interactionsRSK

Identifiers

PMID31678930
PMCPMC6944238
OpenAlexW2983764075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.